Latest Cancer Diagnostics News

INOVIQ Limited reports significant progress in its exosome-based cancer diagnostics and therapeutics, including expanded customer adoption, advanced AI screening tests, and strategic partnerships with leading research centres.

Pacific Edge’s Cxbladder Plus and Triage 1 diagnostic tests are set for significant Medicare reimbursement increases, potentially reshaping the company’s US market prospects.

Telix Pharmaceuticals has gained UK MHRA approval for Illuccix, its advanced prostate cancer PET imaging agent, promising to alleviate supply shortages and improve diagnostic accuracy across the UK.

Cleo Diagnostics has responded to an ASX price query following a notable rise in its share price and trading volume, underscoring its patented ovarian cancer detection technology and ongoing U.S. clinical trials.

Rhythm Biosciences has fast-tracked the integration of the geneType™ business, restoring full commercial capabilities ahead of schedule and setting the stage for expanded market reach.

Cleo Diagnostics reports steady progress in its U.S. and Australian clinical trials for an ovarian cancer blood test, maintaining a solid cash reserve of A$7.3 million as it prepares for FDA submission.

BCAL Diagnostics is poised to launch its innovative BREASTEST® breast cancer diagnostic test in early 2025, backed by recent NATA accreditation, patent acceptance, and a $2.6 million R&D tax offset.

INOVIQ's December quarterly update reveals significant progress in its cancer diagnostic and therapeutic programs, including a highly accurate ovarian cancer screening test and promising breast cancer therapeutics, supported by growing EXO-NET customer adoption and a solid cash position.

Telix Pharmaceuticals has completed a strategic acquisition of ImaginAb, gaining next-generation therapeutic assets and a novel biologics platform to expand its oncology pipeline and R&D capabilities.

Clarity Pharmaceuticals will present compelling data on its 64Cu-SAR-bisPSMA diagnostic agent at two leading oncology conferences, highlighting earlier and more accurate prostate cancer lesion detection than current standards.

Pacific Edge announces a two-month delay in the Medicare Local Coverage Determination for its genetic oncology tests, extending the effective date to April 24, 2025. This extension follows the company’s active engagement with US regulatory bodies.

Clarity Pharmaceuticals has secured a second FDA Fast Track Designation for its 64Cu-SAR-bisPSMA diagnostic agent, aiming to revolutionize prostate cancer imaging and speed regulatory approval.